Related posts
Crypto crumbles as stocks climbStocks, oil and cryptos rallyMarkets rally after Powell’s commentsHe took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.
A long-term fine business and just reported good earnings. It's not in tech or industrials, so it has more stickiness. They made positive plans in their drug pipeline. Seasonally, now is the right time to buy biotech
(Analysts’ price target is $256.05)He bought it last week to diversify and get more exposure in pharmaceuticals. They report next week. Compare to Abbvie which just surprised with drug sales. There's some FT overhang, but shares have been bottoming out recently. If they announce good results, investors will chase this next week.
Facing a patent crisis as proprietary tech is challenged.
Shares have recently sold off.
Will take time to see how prospects play out.
Good hold, but other places to invest for new investors.
Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q
In the last year, 7 stock analysts published opinions about AMGN-Q. 6 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..
Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
7 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.
On 2023-12-01, Amgen Inc. (AMGN-Q) stock closed at a price of $272.45.
They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.